BioSenic and Pluristyx sign term sheet prior to collaboration

Shares of Belgian biotech BioSenic (Euronext: BIOS) were up more than 11% at 0.13 euros today, after it announced the signing of a term sheet with Pluristyx, a leading provider of gene-edited iPSC and cell therapy solutions, with a view to further negotiate the terms and conditions of a potential license and collaboration agreement.

This term sheet will be used as basis for the preparation of a potential wider licensing and collaboration agreement to make BioSenic’s well characterized cells with various original properties available to the market. These cells include immune privilege, anti-inflammatory properties et tissue repair established capacities, both in vitro and in vivo. BioSenic has derived these GMP-manufactured cells from Mesenchymal Stem Cells (MSCs), bone marrow cells from healthy donors.

BioSenic explains that the cells have then been prepared for a number of preclinical and clinical studies. They constitute BioSenic’s investigational medicinal product, ALLOB, which is currently being evaluated in a randomized, double-blind, placebo-controlled Phase IIb study in patients with high-risk tibial fractures.